Company Description
NeOnc Technologies Holdings, Inc., a clinical-stage life sciences company, focuses on the development and commercialization of central nervous system therapeutics designed to overcome the blood-brain barrier.
The company’s NEO drug development platform produces a portfolio of novel drug candidates and delivery methods with patent protections.
Its NEO100-01 and NEO100-02 therapeutics are in Phase II, and the NEO100-03 and NEO212 therapeutics are in Phase I clinical trials, advancing under FDA Fast-Track and Investigational New Drug status.
NeOnc Technologies Holdings, Inc. was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
The company was founded in 2008 and is based in Westlake Village, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Thomas Chen |
Contact Details
Address: Two Dole Drive Westlake Village, California 91362 United States | |
| Phone | 310-663-7831 |
| Website | neonctech.com |
Stock Details
| Ticker Symbol | NTHI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001979414 |
| Employer ID | 92-1954864 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas Chen | Chief Executive Officer |
| Keithly Garnett | Chief Financial Officer |
| Patrick Walters | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | SCHEDULE 13D | Filing |
| Apr 11, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 26, 2025 | CERT | Certification by an exchange approving securities for listing |
| Mar 25, 2025 | EFFECT | Notice of Effectiveness |
| Mar 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2025 | 424B4 | Prospectus |